Compare · NRSN vs NVO
NRSN vs NVO
Side-by-side comparison of NeuroSense Therapeutics Ltd. (NRSN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRSN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 6893.6x NRSN ($26.6M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for NRSN).
- NVO has more recent analyst coverage (25 ratings vs 1 for NRSN).
- Company
- NeuroSense Therapeutics Ltd.
- Novo Nordisk A/S
- Price
- $0.76+1.01%
- $41.01-4.51%
- Market cap
- $26.6M
- $183.15B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 8
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NRSN
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Announces Pricing of Insider-Led PIPE Financing
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- NeuroSense Granted Brazilian Patent Covering PrimeC Composition
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
- SEC Form 6-K filed by NeuroSense Therapeutics Ltd.
- SEC Form 4 filed by Eisenberg Or
- SEC Form 3 filed by new insider Eisenberg Or
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care